Mild cognitive impairment and early Alzheimer's disease eligibility for disease modification therapies in a tertiary centre for cognitive disorders: A simultaneous real‐word study on aducanumab and lecanemab
Amongst subjects diagnosed with mild AD and mild cognitive impairment in a tertiary centre for cognitive disorders, only a small percentage of patients using RCT diagnostic criteria are eligible for DMT. The application of Cummings criteria strongly increased the DMT candidates. Nevertheless, the majority of patients with cognitive disorders have been excluded from DMTs approved so far.
Authors
- Alessia Giugno (ORCID: https://orcid.org/0000-0002-9366-1582)
- Salvatore Nigro (ORCID: https://orcid.org/0000-0001-7566-7983)
- Daniele Urso (ORCID: https://orcid.org/0000-0002-4503-0110)
- Alessandro Introna (ORCID: https://orcid.org/0000-0002-3141-6442)
- Giancarlo Logroscino (ORCID: https://orcid.org/0000-0003-0423-3242)
- Rita Maria Elisa Barone (ORCID: https://orcid.org/0000-0001-6302-2686)
- Davide Vilella (ORCID: https://orcid.org/0009-0008-5319-7050)
- Valentina Gnoni (ORCID: https://orcid.org/0000-0003-3181-0842)
- A. Di Castri
- Chiara Zecca (ORCID: https://orcid.org/0000-0002-7855-5714)
- Roberto De Blasi (ORCID: https://orcid.org/0000-0002-8556-8572)
Institutions
- University of Bari Aldo Moro (IT)
Publication Details
- Journal
- European Journal of Neurology
- Published
- 2024-11-05
- DOI
- https://doi.org/10.1111/ene.16534
- Citations
- 11
- Primary Topic
- Dementia and Cognitive Impairment Research
- Type
- article
- Field-Weighted Citation Impact
- 4.24
Funders
- Biogen
- China University of Petroleum, Beijing
- Eisai
- Regione Puglia
- Genentech